RESUMO
ABSTRACT The 28-spotted hadda beetle Henosepilachna vigintioctopunctata Fab. (Coleoptera: Coccinellidae) is a poly-phagous pest, commonly infesting solanacious crops including brinjal, Solanum melongena L. Upon its severe infestation on brinjal, it causes considerable damage to the foliage and also to the calyx of fruits. The studies were made to record the seasonal abundance of hadda beetle and identification of its natural enemies present in the region for two consecutive years. The pooled data for two years showed that the maximum number of H. vigintioctopunctata egg clusters on brinjal were recorded in the 27th (0.40 egg cluster/ plant), followed by grub population in 35th (3.78 grubs/ plant), pupae in 33rd and 39th (0.83 pupae/ plant) and adult beetles in 36th (5.48 adults/ plant) standard meteorological weeks, respectively. It was observed that the key meteorological factors had 35.9%, 87.3%, 66.8% and 81.9% effect on the abundance of egg clusters, grubs, pupae and adults respectively in summer planted brinjal crop. Two natural enemies of hadda beetle viz. Tetrastichus sp. (egg parasitoid) and Pediobius foveolatus (pupal parasitoid) were recorded. The maximum parasitisation by Tetrastichus sp. and P. foveolatus on the egg clusters and pupae was recorded 22.64% and 6.62% respectively, during the month of August (34th and 35th standard meteorological week respectively). Further, the morphometric parameters of these two adult parasitoids were recorded and greater morphometric variability was observed in P. foveolatus in comparison to Tetrastichus sp.
RESUMO
BACKGROUND: Approximately one-third of patients undergoing total hip replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement. A topical application is easy to administer, provides a maximum concentration of tranexamic acid at the bleeding site, and is associated with little or no systemic absorption of the tranexamic acid. METHODS: A double-blind, randomized controlled trial of 161 patients undergoing unilateral primary total hip replacement investigated the effect of topical (intra-articular) application of tranexamic acid on blood loss. The primary outcome was the blood transfusion rate. Secondary outcomes included the drain blood loss, hemoglobin concentration drop, generic quality of life (EuroQol), Oxford Hip Score, length of stay, a cost analysis, and complications. RESULTS: Tranexamic acid reduced the absolute risk of blood transfusion by 19.6% (95% confidence interval [CI], 6.9% to 32.1%; p = 0.004), from 32.1% to 12.5%, and reduced blood loss by 129 mL (95% CI, 47 to 211 mL; p = 0.002), the hemoglobin concentration drop by 0.84 g/dL (95% CI, 0.41 to 1.27; p < 0.0001), the length of stay by 1.0 days (95% CI, -0.2 to 2.3 days; p = 0.109), and the cost per episode by £305 (95% CI, £0 to £610; p = 0.05). (In 2010, £1 = 1.5 U.S. dollars.) Oxford Hip Scores and EuroQol scores were similar at three months. CONCLUSIONS: Topically applied tranexamic acid was effective in reducing blood loss and the need for blood transfusion following total hip replacement, avoiding the potential complications of intravenous tranexamic acid administration. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.